Date: 2012-05-01
Type of information: Collaboration agreement
Compound: HercepTest™ and HER2 FISH pharmDx™ as companion diagnostics for trastuzumab emtansine (T-DM1)
Company: Dako (Denmark) Genentech a member of the Roche Group (USA-Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease: advanced HER2-positive breast cancer
Details: * On May 1, 2012, Dako has announced that it has entered into collaboration with Genentech on the FDA regulatory submissions of Dako’s HercepTest™ and HER2 FISH pharmDx™ as companion diagnostics for in patients with advanced HER2-positive breast cancer. Under the terms of the agreement, Dako and Genentech will collaborate on the regulatory FDA submissions of HercepTest™ and HER2 FISH pharmDx™ to identify cancer patients who may be eligible for treatment with trastuzumab emtansine.
This announcement comes on the heels of another collaboration between Dako and Genentech on the regulatory submissions of Dako’s HercepTest™ and HER2 FISH pharmDx™ as companion diagnostics for pertuzumab. This agreement has been concluded in December 2011.
Financial terms:
Latest news:
